Dangerous Drug: Dacarbazine (DTIC, Imidazole Carboxamide)(da kar’ ba zeen)
DTIC-Dome
PREGNANCY CATEGORY C
Drug Classes
Alkylating agent
Antineoplastic
Therapeutic Actions
Cytotoxic: Exact mechanism of action unknown; inhibits DNA and RNA synthesis, causing cell death; cell cycle nonspecific.
Indications
Metastatic malignant melanoma
Hodgkin disease—second-line therapy in combination with other drugs
Unlabeled uses: Malignant pheochromocytoma with cyclophosphamide and vincristine; metastatic soft tissue sarcoma; alone or in combination therapy for Kaposi sarcoma; alone or in combination for the treatment of neuroblastomas, fibrosarcoma, rhabdomyosarcoma, islet-cell carcinoma, medullary carcinoma of the thyroid
Contraindications and Cautions
Contraindicated with allergy to dacarbazine, lactation.
Use cautiously with impaired hepatic function, bone marrow depression, pregnancy, lactation; choose another method of feeding a baby.
Available Forms
Powder for injection—100, 200 mg
Dosages
Adult and pediatric malignant melanoma: 2–4.5 mg/kg/day IV for 10 days, repeated at 4-wk intervals or 250 mg/m2 per day IV for 5 days, repeated every 3 wk.
Adult Hodgkin disease: 150 mg/m2 per day for 5 days in combination with other drugs, repeated every 4 wk or 375 mg/m2 on day 1 in combination with other drugs, repeated every 15 days.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
